Concepedia

Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-Ambulant Patients with Duchenne Muscular Dystrophy: An Observational Multicenter Trial

A. Seferian, A. Moraux, M. Annoussamy, Aurélie Canal, V. Decostre, Oumar Diebate, Anne‐Gaëlle Le Moing, Teresa Gidaro, Nicolas Deconinck, F. Van Parys,

PLoS ONE · 2015 · 75 citations · 33 references

DOIFull text

Open access

Abstract

ClinicalTrials.gov NCT00993161 NCT00993161.

References

33

ATS Statement

American Journal of Respiratory and Critical Care Medicine · 2002 · 10.5K citations

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

K. Bushby, Richard S. Finkel, David J. Birnkrant et al. · The Lancet Neurology · 2009 · 2K citations

, , +9

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Sebahattin Çirak, Virginia Arechavala‐Gomeza, Michela Guglieri et al. · The Lancet · 2011 · 852 citations · Full text

, , +4

Eteplirsen for the treatment of Duchenne muscular dystrophy

Jerry R. Mendell, Louise R. Rodino‐Klapac, Zarife Sahenk et al. · Annals of Neurology · 2013 · 770 citations · Full text

Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy

Nathalie Goemans, M. Tulinius, Johanna T. van den Akker et al. · New England Journal of Medicine · 2011 · 659 citations · Full text